BRCA1 and ovarian carcinoma: Unfortunately, no significant improvement has been achieved in the last three decades, except for BRCA1/2 mutated tumors where poly-ADP-ribose polymerase (PARP) inhibitors slightly shifted the care paradigm for ovarian carcinoma.4 However, accumulating evidence is showing that tumor-immune microenvironment (TME) in ovarian carcinoma can open the door for the discovery of new prognostic markers and the development of immunotherapeutic treatment approaches.